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Introduction: Hospital patients recovering from critical illness on general floors often receive 
insulin therapy based on protocols designed for patients admitted directly to general floors. The 
objective of this study is to compare glycemic control and insulin dosing in patients recovering 
from critical illness and those without prior critical illness.
Methods: Medical record review of blood glucose measurements and insulin dosing in 
25 patients under general ward care while transitioning from the intensive care unit (transition 
group) and 25 patients admitted directly to the floor (direct floor group).
Results: Average blood glucose did not differ significantly between groups (transition 
group 9.49 mmol/L, direct floor group 9.6 mmol/L; P = 0.83). Significant differences in 
insulin requirements were observed between groups with average daily doses of 55.9 units in 
patients transitioning from the intensive care unit (ICU) versus 25.6 units in the direct floor 
group (P = 0.004).
Conclusions: Patients recovering from critical illness required significantly larger doses of 
insulin than those patients admitted directly to the floor. Managing insulin therapy in patients 
transitioning from the ICU may require greater insulin doses.
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Introduction
While much attention has been paid to determining optimal targets for critically ill 
patients, the process of transitioning patients from insulin therapy in the intensive care 
unit (ICU) to general ward care has not been studied and previously has been ignored 
by clinicians. The association between high blood glucose and poor patient outcomes 
in a variety of hospital care settings has prompted institutions to develop protocols to 
optimize glycemic control in various patient care areas.1 In patients recovering from 
critical illness, these protocols use previous intravenous insulin rates to calculate 
subcutaneous insulin dosing.2 In contrast, subcutaneous insulin doses for patients 
admitted directly to general wards are based on either previous home insulin doses or 
weight.3,4 While controlled evidence is lacking, the American Diabetes Association 
recommended blood glucose targets are fasting readings of 6.99 mmol/L and maximal 
readings of 9.99–11.1 mmol/L in noncritically ill inpatients.4
A number of factors contribute to hyperglycemia and complicate blood glucose man-
agement in critically ill and noncritically ill patients. The stress of either injury or illness 
leads to insulin resistance, glucose intolerance, and hyperglycemia, and has been termed Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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‘diabetes of injury’.5,6 Illness and trauma stimulate hepatic 
gluconeogenesis even in the presence of hyperglycemia and 
increased insulin production. Uptake of glucose into skeletal 
muscles is impaired. The level of hyperglycemia stimulated 
by these mechanisms is related to the severity of illness.6 
Critically ill patients have more profound insulin resistance 
and have greater insulin requirements than noncritically ill 
patients.2 As patients recover from illness, increased glucose 
production and insulin resistance subside.
While the physiological mechanisms of hyperglycemia in 
critically ill and noncritically ill patients are similar, the degree 
of hyperglycemia and insulin requirements are   different due 
to the variation in disease process severity.2 Several issues 
related to the care of patients recovering from critical illness 
distinguish them from those patients not recovering from criti-
cal illness, including resolution of severe stress-related hyper-
glycemia, the use of glucocorticoids for adrenal insufficiency, 
and the use of continuous enteral or parenteral nutrition.
Despite these differences, there are no studies comparing 
glycemic control and insulin requirements between patients 
recovering from critical illness and those who are not. 
Therefore, the primary objective of this study was to com-
pare inpatient glycemic control in patients recovering from 
critical illness and those admitted directly to a general floor 
(in other words, those not recovering from critical illness). 
The secondary objective was to compare insulin require-
ments between these two populations. We hypothesize that 
patients recovering from critical illness will have less optimal 
glycemic control and greater insulin requirements than those 
not recovering from critical illness.
Methods
This retrospective, observational pilot study was conducted 
at a 649-bed, tertiary, community, academic medical center. 
The local institutional review board approved this study, and 
a waiver of informed consent was granted. A standardized 
protocol based on guidelines from the American Diabetes 
Association to enhance the use of subcutaneous insulin had 
been previously implemented.7 Primary outcome measures 
for this study were average daily blood glucose and average 
daily insulin dose. Secondary outcomes included the propor-
tion of readings above the recommended goal (9.99 mmol/L) 
and the proportion of readings in the hypoglycemic range 
(defined as a blood glucose reading #3.33 mmol/L).8
Patients receiving subcutaneous insulin between December 
2007 and July 2008 were screened for study inclusion. Patients 
in the group transitioning from a critical care unit (transition 
group), had previously received $24 hours of intravenous 
insulin therapy in either the medical or surgical ICU and 
received subcutaneous insulin using the standard protocol when 
transitioned to either general medical or surgical wards. An 
abbreviated version of this protocol is found in Figure 1. For 
inclusion in the direct floor admission group, patients received 
subcutaneous insulin using the standard protocol and were 
admitted to either general medical or surgical floors during 
the study period. Patients admitted for diabetic ketoacidosis 
or hyperosmolar coma, patients receiving oral or intravenous 
corticosteroid therapy, patients with type I diabetes, patients 
who were pregnant, and patients who were immediately postop-
erative from cardiac surgery were excluded from this study.
Paper and electronic medical records of patients while on the 
general floor were reviewed for data collection.   Demographic 
data collected included age, gender, height, and weight. His-
tory of type 2 diabetes and admitting   diagnosis (categorized 
as medical or surgical) were   collected. In the transition group 
the number of ICU days was also obtained. Factors affecting 
blood glucose, including orders for   dextrose-containing IV 
fluids and dietary orders were recorded. All available point-
of-care blood glucose measurements, scheduled insulin doses 
administered, and correction factor (as needed) insulin doses 
administered were documented. Insulin doses were also calcu-
lated on a unit per kilogram basis. Data were recorded for the 
patient’s stay on the floor, up to 10 days. If a patient’s length 
of stay exceeded 10 days, blood glucose and insulin data were 
not collected after the 10th day. This cut-off was established 
because in both patients transitioning from the ICU and those 
admitted directly to the floor, stabilization in blood glucose 
and insulin doses was expected by day 10.8
Previous studies were not available for sample size 
analysis; therefore a convenience sample size of 25 patients 
per group was selected to provide pilot data in this area. 
Demographic variables such as age, height, and weight, and 
outcome variables including average blood glucose measure-
ments and insulin doses were compared using an unpaired 
Student’s t-test. Data on past medical history of diabetes, 
use of enteral nutrition and dextrose-containing IV fluids, 
and proportion of readings outside goal range were assessed 
using Chi square analysis.
All statistical analyses were performed using SPSS 
  version 17.0 (StataCorp, College Station, TX) and Excel 
2003 (Microsoft, Redmond, WA). A P value of ,0.05 was 
set to indicate statistical significance.
Results
Patients in the direct floor group (n = 25) were admitted 
between November 2007 and March 2008; and patients in the Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Institutional Insulin Protocol 
Goal Blood Glucose: Fasting less than 6 mmol/L OR Random less than 10mmol/L
1.  Discontinue all previous insulin orders 
2.  Check fingerstick blood glucose (at least one choice must be selected)
 Before meals and at bedtime every 6 hours (0000, 0600, 1200, 1800)  
At 0300      _______  Hours after meals      other:  __________________________
3.  Basal and Prandial Insulin – Check agent(s) to be used  
New start: Consider 0.5 unit/kg of body weight then divide total daily dose such that ½ doses is basal and other
½ is divided to cover meals. 
Breakfast  Lunch  Dinner  Bedtime 
Basal Long Acting Insulin  Lantus (glargine)
(once daily or divided for large dose)   ______ units  ______ units 
Prandial Rapid Acting Insulin  Novolog (aspart)
Administer with meals (may give with first bite) ______ units  ______ units  ______ units  
4.  Correction Insulin – Novolog (aspart) - Check desired algorithm
Blood 
Glucose
(mmol/L)
Low Dose Algorithm  
(suggested if patient receiving less
than 40 units/day)  
Medium Dose 
Algorithm (suggested
if patient receiving
40 – 80 units/day)  
High Dose Algorithm  
(suggested if patient receiving greater
than 80 units/day)  
Individualized 
Algorithm  
8.32 – 11.0 1 unit2  units3  units
11.1 – 13.8 2 units 4 units 6 units
13.9 – 16.6 3 units 6 units 9 units
16.7 – 19.4 4 units 8 units 12 units
> 19.5 5 units 10 units1 5 units
Diabetes Education Consult.  
Draw HgbA1c with next a.m. labs if not already obtained this admission.  
Notify MD for blood glucose less than ____________ mmol/L or greater than ____________ mmol/L.
5.  Nursing:
• If two consecutive non-fasting glucose readings are10 mmol/L or greater, advance to next higher Correction Algorithm.  If patient is 
receiving the High Dose Correction Algorithm and has two consecutive non-fasting glucose readings greater than 180 mg/dL, notify MD.
• Hold prandial if patient NPO or not taking a meal; notify MD if patient not eating.  DO NOT HOLD BASAL.
• If pre-meal FSBG (finger stick blood glucose) is:  
4.4 mmol/L or greater, give full-dose of prandial insulin, as long as patient is eating meals
Below 4.4 mg/dL, do NOT give prandial insulin  
• Correction insulin may be added to prandial insulin dose (if ordered) and administered in same syringe with meal. 
•I nitiate Hypoglycemia Protocol for finger stick blood glucose less than 3.33 mol/L.
6. Titration of Basal Insulin [Lantus (glargine)]: Adjust every other day from start of most recent order.
Average a.m. (fasting) glucose for today and yesterday Basal (Lantus) Insulin  
Less than 4.4 mmol/L   Decrease by 2 units  
4.4  - 6.0 mmol/L   No change 
6.1 - 7.2 mmol/L   Increase  2 units/day  
7.3 - 8.3 mmol/L   Increase  4 units/day  
8.4  - 10 mmol/L   Increase  6 units/day  
> 10 mmol/L   Increase  8 units/day  
Figure 1 insulin protocol for inpatients
transition group (n = 25) were admitted between November 
2007 and July 2008. The extended interval for inclusion of 
ICU transition patients was needed because of a low number 
of ICU patients receiving intravenous insulin for $24 hours. 
Patient characteristics are shown in Table 1. Age and history 
of diabetes differed statistically between groups. There was 
also a trend toward significance in weight and body mass 
index (BMI) with transition patients having greater weight 
and BMI. A total of 805 and 534 blood glucose readings were 
collected in the transition and direct floor groups, respec-
tively. Data were collected over an average of 7.3 days in the 
transition group and 5.1 days in the direct floor group.Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Types of nutrition varied among ICU transition and direct 
floor admit patients with 20 patients in the transition group 
receiving supplemental enteral nutrition via tube compared 
with one patient in the direct floor group. Other patients 
received an oral diet. There was no difference between groups 
with respect to dextrose-containing IV fluids.
Average daily blood glucose did not differ significantly 
between groups (Table 2). The ICU transition group had 
an average of 9.49 ± 1.89 mmol/L, and the direct floor 
group had an average of 9.6 ± 2.1 mmol/L (α = 0.05, 
β = 94.6, P = 0.83). Patients in the direct floor group had a 
greater proportion of readings greater than or equal to the 
  recommended target $9.99 mmol/L, with 37.6% in the 
ICU transition group versus 44% in the direct floor group 
(P = 0.02). There was a low incidence of hypoglycemia 
(blood glucose # 3.33 mmol/L) in the study with a nonsig-
nificant difference in hypoglycemic readings in each group 
(transition 0.87%, direct floor 1.31%, P = 0.43).
Significant differences in blood glucose were observed 
among average blood glucose for individual days (Figure 2). 
On study day 1, ICU transition patients had significantly 
lower average blood glucose than direct floor admit patients. 
Groups were similar on days 2–7. As the study progressed 
on days 8–10, ICU transition patients had higher average 
blood glucoses.
There were significant variations in insulin doses 
between groups (Table 3). Patients transitioning from ICU 
care received total average daily insulin doses of 55.9 units 
compared with 25.6 units in patients admitted directly to the 
floor (P = 0.004). These differences remained statistically 
significant on a unit per kilogram basis with an average daily 
dose of 0.58 units/kg in the transition group and 0.32 units/kg 
in the direct floor group (P = 0.02). These differences were 
observed in both scheduled and correction factor insulin 
doses. In addition, total average daily insulin dose for each 
day of the study period was examined. There were no changes 
in average insulin doses over time.
Discussion
The present study failed to find a difference in average daily 
blood glucose in patients recovering from critical illness and 
those without prior critical illness. This refutes our initial 
hypothesis. The key finding from this study is an increase 
in insulin requirements to maintain similar levels of glyce-
mic control in patients recovering from critical illness. To 
our knowledge, this is the first study to compare glycemic 
control and insulin doses between patients recovering and 
not recovering from critical illness.
We hypothesized that a wide variety of factors affecting 
blood glucose in patients transitioning from ICU care would 
have led to poorer glycemic control in those patients. One 
expected factor is the increased use of enteral nutrition in the 
ICU transition group. The similarity in blood glucose between 
groups is explained by the increased insulin doses in ICU 
patients. Patients in the ICU transition group were converted 
to subcutaneous insulin while still in the ICU. Higher blood 
glucose readings were likely to occur during this initial transi-
tion period in the ICU prior to data collection while insulin 
doses were refined and optimized. In contrast, patients admitted 
directly to the floor began insulin therapy while data collection 
was underway. We suspect that poorer glycemic control was 
more likely during this period of insulin initiation. Patients in 
the ICU group had a similar number of daily blood glucose 
readings performed. The greater number of blood glucose read-
ings performed is reflective of their increased length of stay.
A number of previous studies have examined inpa-
tient glycemic control using basal-bolus insulin therapy 
and protocols among patients admitted directly to general 
medical or surgical floors.9–12 While these studies exclude 
patients with prior critical illness, they do provide blood 
glucose data comparable to measurements observed in the 
present study in patients without prior critical illness. In the 
first, prospective, randomized study of basal-bolus insulin 
therapy, an   average blood glucose of 9.21 ± 1.78 mmol/L 
was observed in the treatment group.9 The authors also 
observed a decrease in blood glucose over the study period. 
The present study results are comparable to these findings 
with similar variability in average blood glucose and in 
the trend of a decrease in average daily blood glucose over 
Table 1 Patient characteristics
ICU transition Direct floor P-value
Age (years) 57 ±10 64 ± 12 0.023
gender (males) (no.) 14  14 1
Weight (kg) 99.5 ± 35.4 83.7 ± 18.9 0.055
Body mass index (kg/m2) 35.4 ± 15.9 28.5 ± 5.7 0.052
iCU stay (days) 12.1 ± 7.9 – –
Medical admitting  
diagnosis (no.)
16  18 0.544
Past medical history  
of diabetes (no.)
19 24 0.041
Table 2 Blood glucose
ICU transition Direct floor P-value
Average daily blood 
glucose (mmol/L)
9.49 ± 2.11 9.60 ± 1.89 0.83
readings $ 9.99 mmol/L 303/805 (37.6%) 235/534 (44%) 0.02
readings # 3.33 mmol/L 7/805 (0.87%) 7/534 (1.31%) 0.44Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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the study period. Fasting   readings in the treatment group 
were 8.16 ± 2 mmol/L. While the retrospective nature of 
the present study limited the ability to record fasting read-
ings, average first morning blood glucose readings over 
the study period were 8.44 ± 3.16 mmol/L. In addition, the 
prospective study also demonstrated a trend of decreasing 
average blood glucose from   approximately 12.77 mmol/L 
on study day 1 to 7.77 mmol/L on study day 10. Our study 
demonstrated a similar decrease in readings over the study 
period with average blood glucose on day 1 of 11.27 mmol/L 
and 7.27 mmol/L on day 10. The parallel fasting readings 
and trends in blood glucose confirm the blood glucose data 
in direct floor admission patients in our study.
After this study was conducted, Czosnowski et al13 evalu-
ated glycemic control in patients following discontinuation 
from intravenous insulin. Mean blood glucose during the 
last 12 hours on an intensive insulin protocol with intra-
venous therapy was compared to mean blood glucose for 
five days following discontinuation. In a cross-over design 
of 65 patients, a statistically significant increase in mean 
blood glucose was observed when measurements from the 
intensive insulin period were compared with each day of 
the follow-up period. Also, they observed a nonsignificant 
trend of increasing average blood glucose over the 5-day 
study period with average daily blood glucose measurements 
between 8.99 ± 2.72 mmol/L and 9.82 ± 3.12 mmol/L. The 
ICU transition patients in this study also exhibited similar 
average daily blood glucose ranges and increases in average 
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Figure 2 Comparison of daily average blood glucose.
Table 3 Total insulin doses (units) 
ICU transition Direct floor P value
Average daily insulin  
dose per patient day
55.9 25.6 0.004
Average weight-based  
daily insulin dose (units/kg)
0.58 0.32 0.02
Total average scheduled 
insulin
142.5 59.5 0.0001
Total average correction 
factor
47.0 25.2 0.001Clinical Pharmacology: Advances and Applications
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daily blood glucose over the study period. The combined 
evidence from the present study and that of Czosnowski 
et al highlight problems with glycemic control in patients as 
they transition from intravenous insulin. This study validates 
the results seen in the ICU transition group of the present 
study.
Limitations of this study include small sample size and 
retrospective study design. Small sample size may have 
  contributed to a nearly significant difference in weight 
between groups and large variability in blood glucose and 
insulin doses. The retrospective study design introduced 
bias as differences in nondocumented nutritional intake 
could not be assessed. It also led to an insufficient num-
ber of hemoglobin a1c readings for comparison between 
groups. Data collection occurred for more days in the ICU 
transition group due to a longer length of stay. However, 
as noted in Figure 2, blood glucose in the ICU transition 
group remained relatively stable throughout the hospital 
stay.
Despite small sample size, blood glucose readings within 
this study were similar to those observed in previous studies 
evaluating patients admitted directly to the floor and those 
observed in a recent study evaluating patients transitioning 
from ICU care. In addition, the increasing average daily blood 
glucose in the ICU transition group and decreasing average 
daily blood glucose in the direct floor admission group is 
similar to that of previous studies. The present study also 
demonstrated a statistically significant increase in insulin 
dosing that was maintained after standardization for weight 
on a unit per kilogram basis.
Conclusion
Patients transitioning from critical care units are at increased 
risk for hyperglycemia compared to patients without prior 
critical illness. We found that higher doses of insulin are 
required in patients recovering from critical illness to attain 
glycemic control similar to patients without prior   critical 
  illness. In managing blood glucose with subcutaneous 
  insulin, larger insulin doses should be considered in patients 
  recovering from critical illness. Future studies regarding 
specific insulin dosing are required to determine optimal 
dosing regimens for this population.
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